CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma

Leukemia Research

Volumn 36, Issue 11, 2012, Pages 1422-1427

  Sanchez, Eric ^a   Li, Mingjie ^a   Li, Jennifer ^a   Wang, Cathy ^a   Chen, Haiming ^a   Jones Bolin, Susan ^b   Hunter, Kathryn ^b   Ruggeri, Bruce ^b   Berenson, James R ^a  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b Teva Pharmaceuticals Inc   (United States)

Author keywords

Delanzomib; Dexamethasone; In vivo; Inhibitors; Lenalidomide; Multiple myeloma; Proteasome

Indexed keywords

DELANZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN G; LENALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TUMOR VOLUME; WEIGHT CHANGE; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CELL LINE, TUMOR; DEXAMETHASONE; HUMANS; MICE; MICE, SCID; MULTIPLE MYELOMA; THALIDOMIDE; THREONINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866341173     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.07.018     Document Type: Article

References (49)

1. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F.E., Tai Y.T., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96:2943-2950.
2. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y.T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98:210-216.
3. Weber D.M., Rankin K., Gavino M., Delasalle K., Alexanian R. Thalidomide with dexamethasone for resistant multiple myeloma. Blood 2000, 96:167a. [abstract].
4. Rajkumar S.V., Hayman S.R., Gertz M.A., Dispenzieri A., Lacy M.Q., Greipp P.R., et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed multiple myeloma. J Clin Oncol 2002, 20:4319-4323.
5. Richardson P.G., Schlossman R.L., Weller E., Hideshima T., Mitsiades C., Davies F., et al. Immunomodulatory drug CC5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063-3067.
6. Rajkumar S.V., Hayman S.R., Lacy M.Q., Dispenzieri A., Geyer S.M., Kabat B., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005, 106:4050-4053.
7. Rajkumar S.V., Blood E., Vesole D.H., Fonseca R., Greipp P.R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006, 24:431-436.
8. Rajkumar S.V., Rosinol L., Hussein M., Catalano J., Jedrzejczak W., Lucy L., et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008, 26:2171-2177.
9. Rajkumar S.V., Jacobus S., Callander N., Fonseca R., Vesole D., Greipp P. A randomized phase III trial of lenalidomide plus high-dose dexamethasone vs lenalidomide plus low dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 2006, 108:799. [abstract].
10. Lacy M.Q., Gertz M.A., Dispenzieri A., Hayman S.R., Geyer S., Kabat B., et al. Long term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007, 82:1179-1184.
11. Ma M.H., Yang H.H., Parker K., Manyak S., Friedman J.M., Altamirano C., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003, 9:1136-1144.
12. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
13. Jagannath S., Durie B.G., Wolf J., Camacho E., Irwin D., Lutzky J., et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005, 129:776-783.
14. Harousseau J.L., Attal M., Leleu X., Troncy J., Pegourie B., Stoppa A.M., et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006, 91:1498-1505.
15. Harousseau J.L. Induction therapy in multiple myeloma. Hematology Am Soc Hematol Educ Program 2008, 306-312.
16. Richardson P.G., Weller E., Jagannath S., Avigan D.E., Alsina M., Schlossman R., et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009, 27:5713-5719.
17. Alexanian R., Dimopoulos M. Treatment of multiple myeloma. N Engl J Med 1994, 330:484-489.
18. Sanchez E., Li M., Steinberg J.A., Wang C., Shen J., Bonavida B., et al. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol 2010, 148:569-581.
19. Richardson P.G., Weller E., Lonial S., Jakubowiak A.J., Jagannath S., Raje N.S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
20. Campbell R.A., Berenson J.R. Animal models of multiple myeloma and their utility in drug discovery. Current protocols in pharmacology 2008, vol. 40. John Wiley & Sons, Inc., Hoboken, JN, Unite 14.9, p. 14.9.1-14.9.22.
21. Bissery M.-C., Guenard D., Gueritte-Voeglein F., Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991, 51:4845-4852.
22. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
23. Dispenzieri A., Jacobus S., Vesole D.H., Callandar N., Fonseca R., Greipp P.R. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia 2010, 24:1406-1411.
24. Piva R., Ruggeri B., Williams M., Costa G., Tamagno I., Ferrero D., et al. CEP-18770: a novel orally-active proteasome inhibitor with a tumor-selective pharmacological profile competitive with bortezomib. Blood 2008, 111:2765-2775.
25. Dorsey B.D., Iqbal M., Chatterjee S., Menta E., Bernardini R., Bernareggi A., et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 2008, 51:1068-1072.
26. Dick L.R., Fleming P.E. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010, 15:243-249.
27. Chauhan D., Singh A.V., Ciccarelli B., Richardson P.G., Palladino M.A., Anderson K.C. Combination of novel proteasome inhibitor NPI-0052 and lenaliomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 2010, 115:834-844.
28. Chauhan D., Singh A.V., Aujay M., Kirk C.J., Bandi M., Ciccarelli B., et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 2010, 116:4906-4915.
29. Chauhan D., Tian Z., Zhou B., Kuhn D., Orlowski R., Raje N., et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011, 17:5311-5321.
30. Kuhn D.J., Chen Q., Voorhees P.M., Strader J.S., Shenk K.D., Sun C.M., et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007, 110:3281-3290.
31. Fenical W., Jensen P.R., Palladino M.A., Lam K.S., Lloyd G.K., Potes B.C. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg Med Chem 2009, 17:2175-2180.
32. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 2005, 8:407-419.
33. Chauhan D., Singh A.V., Brahmandam M., Podar K., Hideshima T., Richardson P., et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008, 111:1654-1664.
34. Jagannath S., Vij K., Stewart K. Final results of PX-171-003-A0, part 1 of an open-label, single arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma. J Clin Oncol 2009, 27(15s):8504. [abstract].
35. Berenson J.R., Yellin O., Dichmann R., Patel-Donnelly D., Boccia R.V., Hilger J.D., et al. A phase I/II study of carfilzomib (CFZ) as a replacement for bortezomib (BTZ) for multiple myeloma (MM) patients (Pts) progressing while receiving a BTZ-containing combination regimen. J Clin Oncol 2012, 30:8098. [abstract].
36. Jakubowiak A.J., Dytfeld D., Griffith K., Jagannath S., Vesole D.H., Anderson T., et al. Carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed myeloma: updated results of Phase I/II MMRC Trial. International Myeloma Workshop 2011, [abstract 318].
37. Jagannath S., Barlogie B., Berenson J., Siegel D., Irwin D., Richardson P.G., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004, 127:165-172.
38. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99:4525-4530.
39. Campbell R.A., Sanchez E., Steinberg J.A., Baritaki S., Gordon M., Wang C., et al. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol 2007, 138:467-478.
40. Podar K., Raab M.S., Zhang J., McMillin D., Breitkreutz I., Tai Y.T., et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007, 109:1669-1677.
41. Pei X.Y., Dai Y., Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004, 10:3839-3852.
42. Mitsiades N., Mitsiades C.S., Richardson P.G., Poulaki V., Yu-Tzu T., Chauhan D., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101:2377-2380.
43. Richardson P.G., Mitsiades C., Schlossman R., Ghobrial I., Hideshima T., Munshi N., et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 2008, 8:1053-1072.
44. Ruschak A.M., Slassi M., Kay L.E., Schimmer A.D. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 2011, 103:1007-1017.
45. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high dose dexamethasone for relapsed myeloma. N Engl J Med 2005, 352:2487-2498.
46. Berenson J.R., Yang H.H., Sadler K., Jarutirasarn S.G., Vescio R.A., Mapes R., et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006, 24:937-944.
47. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M.H., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
48. Berenson J.R., Yang H.H., Vescio R.A., Nassir Y., Mapes R., Lee S.P., et al. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Ann Hematol 2008, 87:623-631.
49. Pineda-Roman M., Zangari M., van Rhee F., Anaissie E., Szymonifka J., Hoering A., et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008, 22:1419-1427.